Literature DB >> 6340493

Membranous glomerulopathy associated with captopril therapy.

S C Textor, G N Gephardt, E L Bravo, R C Tarazi, F M Fouad, R Tubbs, J T McMahon.   

Abstract

Two cases of nephrotic syndrome and biopsy-proved membranous glomerulopathy (membranous glomerulonephritis) were encountered during captopril treatment of 53 hypertensive subjects in our institution. Both patients had impaired renal function before treatment and were treated with 600 mg per day. Discontinuation of captopril led to transient partial remission of proteinuria but was followed by a recurrent, fluctuating course over one year later. Repeat biopsies, eight and 12 months after discontinuation of the drug, demonstrated persistent subepithelial deposits in the glomerular basement membrane. There has been a decline in glomerular filtration rate since discontinuation of the drug, apparently due to arterionephrosclerosis. These studies suggest that glomerular basement membrane deposits in captopril-associated membranous glomerulonephritis are not readily reversible and may be associated with persistent proteinuria, contrary to some previous reports.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340493     DOI: 10.1016/0002-9343(83)91031-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.

Authors:  Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

Review 2.  Selecting appropriate antihypertensive drug dosages.

Authors:  G D Johnston
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

3.  Clinical and histopathologic findings in adults with the nephrotic syndrome.

Authors:  W Medawar; A Green; E Campbell; M Carmody; J Donohoe; G Doyle; J J Walshe
Journal:  Ir J Med Sci       Date:  1990-05       Impact factor: 1.568

Review 4.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 5.  [Membranous glomerulonephritis].

Authors:  S Scheidat; R A K Stahl
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

Review 6.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 7.  Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature.

Authors:  T Isozaki; M Kimura; N Ikegaya; T Arai; Y Fujigaki; A Hishida; E Kaneko
Journal:  Clin Investig       Date:  1992-11

Review 8.  Membranous nephropathy in the older adult: epidemiology, diagnosis and management.

Authors:  Jeroen K J Deegens; Jack F M Wetzels
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

10.  Captopril: 4 years of post marketing surveillance of all patients in New Zealand.

Authors:  I R Edwards; D M Coulter; D M Beasley; D MacIntosh
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.